已发表论文

甲状腺激素变化与合并乳腺癌和原发性甲状腺癌相关

 

Authors Jin J, Li J, Liu Y, Shi Q, Zhang B, Ji Y, Hu P

Received 19 October 2023

Accepted for publication 21 December 2023

Published 9 January 2024 Volume 2024:16 Pages 15—22

DOI https://doi.org/10.2147/BCTT.S442707

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Pranela Rameshwar

Background: Breast cancer and thyroid cancer are two prevalent malignancies in women, and a potential association between the two diseases has been suggested.
Methods: This retrospective case-control study was conducted involving 97 patients with breast cancer and thyroid cancer (BC-TC group) and 97 age-matched patients with breast cancer alone (BC group). Thyroid hormone levels, including triiodothyronine (T3), thyroxine (T4), free triiodothyronine (FT3), free thyroxine (FT4) and thyroid-stimulating hormone (TSH), were analyzed in healthy controls, BC patients, and BC-TC patients.
Results: BC-TC patients exhibited a higher rate of estrogen receptor (ER) and progesterone receptor (PR) positivity compared to BC patients. Serum T3 levels were significantly decreased in BC and BC-TC patients compared to healthy controls. However, there was no significant difference in T3 levels between BC and BC-TC patients. Serum TSH levels were significantly higher in BC-TC patients compared to BC patients.
Conclusion: ER positivity, PR positivity, and serum TSH levels greater than 4.45 mU/L were independent risk factors for primary thyroid cancer in breast cancer patients.

Keywords: breast cancer, thyroid cancer, estrogen receptor, ER